← All stocks

Bicara Therapeutics Inc.

BCAX Net buying

CIK 0002023658 #2204 in the set updated 17 Sep 2026

Bought (120 mo)

$39.05M

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$14.91M

$87.52K on a plan · $14.82M straight out of an exercise

Sold at will

$0.00

0 of 76 sales

Net

+$24.14M

+$39.05M against sales at will

By person

12 insiders · 87 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

RA CAPITAL MANAGEMENT, L.P. entity

Director

$37.79M (3)

—

+$37.79M

4,603,418

6.96%

$107.88M

—

Cohlhepp Ryan

President, COO & Interim CEO

—

$4.60M (29) scheduled

−$4.60M

181,641

0.2745%

$4.26M

−17.9%

Mazumdar Claire

Chief Executive Officer

—

$4.06M (17) scheduled

−$4.06M

362,152

0.5473%

$8.49M

+16.9%

Hyep Ivan

Chief Financial Officer

—

$3.24M (17) scheduled

−$3.24M

129,855

0.1962%

$3.04M

−10.7%

Meisner Lara

Chief Legal Officer

—

$1.87M (5) scheduled

−$1.87M

0.0000%

$0.00

—

Flynn James E

10% owner

$1.26M (2)

—

+$1.26M

897,587

1.36%

$21.03M

—

Raben David

Chief Medical Officer

—

$1.15M (8) scheduled

−$1.15M

55,286

0.0835%

$1.30M

+55.7%

TPG GP A, LLC entity

Former 10% Owner

—

1,960,425

2.96%

$45.94M

—

FMR LLC entity

See Remark 1

—

1,115,333

1.69%

$26.14M

—

Biocon Ltd entity

10% owner

—

1,080,775

1.63%

$25.33M

—

FIL Ltd entity

See Remark 1

—

1,013,853

1.53%

$23.76M

—

Mazumdar-Shaw Kiran

Director

—

432,736

0.6539%

$10.14M

—

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 84

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 8

Sales on a Rule 10b5-1 plan 3

Sales straight out of an exercise 73

Sales at will 0

Transactions with no price 0

Shares from compensation/vesting 23,299,906

History held since 16 Sep 2024